SW · CURN.SW
Curatis Holding AG
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Liestal 4410
- Website
- curatis.com
Price · as of 2024-12-31
$24.40
Market cap 96.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $10.71 | -56.11% |
| Graham-Dodd Method(GD) | $8.20 | -66.38% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $985.60 | $437.76 | $58,561.25 | $0.09 | $1.32 |
| 2011 | $716.80 | $316.09 | $2,029.72 | $0.06 | $0.00 |
| 2012 | $716.80 | $319.07 | $773.28 | $0.03 | $0.00 |
| 2013 | $582.40 | $271.95 | $3.83 | $0.01 | $0.04 |
| 2014 | $358.40 | $171.74 | $0.53 | $0.00 | $0.01 |
| 2015 | $134.40 | $82.57 | $0.00 | $0.00 | $0.24 |
| 2016 | $179.20 | $99.91 | $0.00 | $0.00 | $0.00 |
| 2017 | $123.20 | $83.32 | $0.00 | $0.00 | $0.00 |
| 2018 | $76.16 | $90.78 | $0.00 | $0.00 | $0.00 |
| 2019 | $64.96 | $53.02 | $0.00 | $0.00 | $0.00 |
| 2020 | $358.40 | $176.19 | $0.00 | $0.00 | $0.01 |
| 2021 | $286.72 | $148.46 | |||
| 2022 | $53.76 | ||||
| 2023 | $21.50 | ||||
| 2024 | $11.00 | $10.12 | $8.20 |
AI valuation
Our deep-learning model estimates Curatis Holding AG's (CURN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $24.40
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.71
-56.11% upside
Graham-Dodd
$8.20
-66.38% upside
Graham Formula
—
— upside
About Curatis Holding AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, gastroenterologic, immunomodulator, thyreostatic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema in pediatric patients; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and KIN001 that is in Phase I clinical trial for the treatment of rare inflammatory and fibrotic diseases. The company is based in Liestal, Switzerland.
- CEO
- Roland Rutschmann
- Employees
- 7
- Beta
- 2.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.71 ÷ $24.40) − 1 = -56.11% (DCF, example).